作者: S. Diver , R. J. Russell , C. E. Brightling
DOI: 10.1111/CEA.13086
关键词: Disease control 、 Pharmacotherapy 、 Severe asthma 、 Inflammatory pathways 、 MEDLINE 、 Health care 、 Asthma 、 Drug 、 Intensive care medicine 、 Medicine
摘要: Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people world-wide. In 5%-10% cases, it severe, with disproportionate healthcare resource utilization including costs associated frequent exacerbations and long-term health effects systemic steroids. Characterization pathways in severe asthma has led to development targeted biological small molecule therapies which aim achieve disease control while minimizing corticosteroid-associated morbidity. Herein, we review currently licensed agents those development, speculate how drug therapy for might evolve impact on clinical outcomes near future.